2mo
New evidence highlights the growing role of autoantibodies, circulating microRNAs, and immune biomarkers in improving myasthenia gravis diagnosis and disease monitoring. These emerging tools may help differentiate disease subtypes, assess treatment response, and support more personalized care strategies.
-
Temeki Hill2mo1st I wasn't aware of transient neonatal MS, that is new to me and very interesting to know the signs to look for in an infant but I guess that's another topic. But looking at biomarkers is very important on disease diagnosis, progress or setbacks and managing medications and the need to alter care depending on these biomarkers especially since many medications aren't safe in pregnancy (which the article focuses on, pre and post pregnancy). The more we know about the physiology of this disease process the more ways the chain of inflammatory events can be broken and this is where disease management comes into play because new medications can be developed to break the cycle anywhere in the chain.
-
Morad Daniel2moVery helpful to monitor treatment response.
-
SHABNAM SACHDEVA2moMicro RNA and immune biomarkers improve the diagnostic workup of patients with gMG
-
SACHINKUMAR PANCHAL2moThis can give patients more encouragement and hope
-
Steven Seller2mothese emerging opportunities give patients more hope for future treatments